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  ABSTRACT 
  Background      Evidence is beginning to emerge that there 
may be susceptibility loci for rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) that are common to 
both diseases.   
  Objective      To investigate single nucleotide 
polymorphisms that have been reported to be associated 
with SLE in a UK cohort of patients with RA and controls.   
  Methods      3962 patients with RA and 9275 controls 
were included in the study. Eleven SNPs mapping to 
conﬁ  rmed SLE loci were investigated. These mapped 
to the   TNFSF4, BANK1, TNIP1, PTTG1, UHRF1BP1, 
ATG5, JAZF1, BLK, KIAA1542, ITGAM   and   UBE2L3   loci. 
Genotype frequencies were compared between patients 
with RA and controls using the trend test.   
  Results      The SNPs mapping to the   BLK   and   UBE2L3  
loci showed signiﬁ  cant evidence for association with 
RA. Two other SNPs, mapping to   ATG5   and   KIAA1542 , 
showed nominal evidence for association with RA 
(p=0.02 and p=0.02, respectively) but these were 
not signiﬁ  cant after applying a Bonferroni correction. 
Additionally, a signiﬁ  cant global enrichment in carriage of 
SLE alleles in patients with RA compared with controls 
(p=9.1×10  −7  ) was found. Meta-analysis of this and 
previous studies conﬁ  rmed the association of the   BLK  
and   UBE2L3   gene with RA at genome-wide signiﬁ  cance 
levels (p<5×10  −8  ). Together, the authors estimate that 
the SLE and RA overlapping loci, excluding   HLA-DRB1  
alleles, identiﬁ  ed so far explain ~5.8% of the genetic 
susceptibility to RA as a whole.   
  Conclusion      The ﬁ  ndings conﬁ  rm the association of the 
  BLK   and   UBE2L3   loci with RA, thus adding to the list of 
loci showing overlap between RA and SLE.           
  INTRODUCTION 
  Rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) are both autoimmune rheu-
matological diseases thought to have a substantial 
genetic contribution to susceptibility.    1        2    Recent 
genome-wide association studies (GWAS) in 
both diseases have disclosed a number of genetic 
loci that that are commonly associated. Examples 
include the human leucocyte antigen (HLA) 
locus, the R620W (rs2476601)   polymorphism 
within the   PTPN22   gene and association with 
the   chromosome 6q23/  TNFAIP3   locus.    3        4    The 
high degree of familial aggregation that has 
been shown for RA and SLE further supports the 
  presence of common genetic risk   factors for both 
  diseases.    5        6    
  Recent GWAS in SLE have identiﬁ  ed a number 
of novel associations, some of which have not 
been previously investigated in RA.    4        7     –      10    We have 
reported previously on the overlap between type 
1 diabetes and RA susceptibility loci and there 
are now numerous examples of overlap between 
diverse autoimmune diseases.    11     –      14    We, therefore, 
hypothesised that the underlying autoimmunity 
of SLE and RA may be underpinned by additional 
overlap in the genetic susceptibility loci. The aim of 
this work was to investigate whether single nucle-
otide polymorphism (SNP) markers that had been 
reported to be associated with SLE were also asso-
ciated with RA in a UK population of patients with 
RA and controls.   
  METHODS 
  Samples 
  Three thousand nine hundred and sixty-two 
patients with RA and 9275 controls were included 
in the study. The patients with RA were recruited 
as described previously    15    and all satisﬁ  ed the 1987 
American College of Rheumatology criteria for RA 
modiﬁ  ed for genetic studies.    16        17    The clinical char-
acteristics of the cohort have been described previ-
ously, but brieﬂ  y, 71.8% were female, 72.1% were 
positive for rheumatoid factor and 69.7% positive 
for anticyclic citrullinated peptide (anti-CCP) anti-
bodies. All samples were collected with ethical 
committee approval (MREC 99/8/84) and all indi-
viduals provided informed consent.   
    SNP selection and genotyping 
  A panel of 15 autosomal SNPs was selected for 
investigation from a recent large-scale replication 
study of SLE-associated loci,    10    and proxy SNPs 
were included where assays could not be designed 
for the original SNP tested. 
  Of the 21 SLE loci identiﬁ  ed to date, we have pre-
viously reported association with   PTPN22  ,   STAT4   
and the 6q23/  TNFAIP3   locus.    15        18     –      20    The associa-
tion of   HLA-DRB1   alleles with RA has been exten-
sively studied in the past. Different SNPs mapping 
to the   FCGR2A   gene (rs12746613; r  2  =0.19 with the 
SLE SNP rs1801274) and   PRDM1   (rs548234, r  2  =0.07 
with the SLE SNP rs2245214) have been reported to 
be associated with RA in meta-analysis including 
the samples tested in the current cohort.    21    SNPs 
mapping to the remaining 15 loci were selected 
for investigation. However, four SNPs mapping 
to   IRF5, IRAK1  ,   PXK   and   IL10   either failed assay 
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  Finally, in order to explore how much of the genetic suscep-
tibility to RA could be accounted for by variants identiﬁ  ed to 
date, the sibling recurrence risk ratio (λs) was calculated using 
the formula: 
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  where   q   is the risk allele frequency,   p  =1−  q   and γ is the   genotype 
relative risk under the additive model.     
  RESULTS 
  For the   BANK1  ,   JAZF1   and   BLK   SNPs, data were available 
from a previous GWAS in a UK population including 2000 RA 
cases and 3000 controls.    23    In addition, part of the cohort used 
in our study had been previously genotyped for   UBE2L3  .    24    
Therefore, non-overlapping samples from these studies were 
added to the current cohort for the analysis of the three 
markers. Control allele frequencies for all SNPs tested con-
formed to Hardy–Weinberg expectations (  table 1  ). Four SNPs, 
rs6568431 mapping to the   ATG5   locus, rs2736340 close to   BLK  , 
rs4963128 mapping to the   KIAA1542   locus and rs5754217 in 
  UBE2L3   showed nominal evidence for association (p<0.05). 
After applying a Bonferroni correction for the number of SNPs 
tested, only the SNPs mapping to   BLK   and   UBE2L3   retained 
statistically signiﬁ  cant evidence for association. It should be 
noted that control allele frequencies were similar and the 
direction of association was the same at all four loci with that 
observed in the SLE studies, although effect sizes were smaller. 
Therefore, although non-signiﬁ  cant after applying a Bonferroni 
correction,   ATG5   and   KIAA1542   remain interesting candidates 
for further investigation. Repeating the association analysis 
in the anti-CCP positive and negative subgroups of RA cases 
did not substantially alter the observed effect sizes (data not 
shown). A test of heterogeneity of odds ratios (ORs) showed 
that the effect sizes were similar among all RA, anti-CCP posi-
tive RA and anti-CCP negative RA subgroups for all analysed 
SNPs (p>0.05).   
  A meta-analysis including our UK cohort and the US cohort 
in which association of   BLK   with RA was described for the ﬁ  rst 
time showed a strong association between the rs2736340 SNP 
in the   BLK   locus and RA (p=5.6×10  –11  , OR=1.14 95% CI 1.10 to 
1.19). We also performed a pooled analysis for   UBE2L3  , expand-
ing the validation cohort from the meta-analysis of Stahl   et al      24    
with the UK non-overlapping samples genotyped in our study, 
design or failed genotyping, resulting in 11 SNP markers being 
available for analysis (rs10489265 in   TNFSF4,   rs10516487 in 
  BANK1,   rs10036748 in   TNIP1,   rs2431697 in   PTTG1,   rs11755393 
in  UHRF1BP1,   rs6568431 in  ATG5,   rs864745 in  JAZF1,   rs2736340 
in   BLK,   rs4963128 in   KIAA1542,   rs9888739 in   ITGAM   and 
rs5754217 in   UBE2L3  ). 
  Genotyping was undertaken using a Sequenom platform with 
iPlex chemistry according to manufacturer’s instructions (  http://
www.sequenom.com  ). Quality control analysis was undertaken 
such that only SNPs and samples that passed a 90% quality con-
trol threshold were subject to further statistical analysis. Control 
allele frequencies were tested to ensure that they conformed to 
Hardy–Weinberg expectations, and SNPs that deviated signiﬁ  -
cantly from this were removed from further analysis.   
  Analysis 
  First, genotype frequencies were compared between RA cases 
and controls using the χ  2   trend test implemented in PLINK soft-
ware    22    to determine whether individual SLE susceptibility loci 
were also associated with RA. Where data were available for 
SLE variants in independent RA samples, data from this study 
were added to the data already available and reanalysed to 
determine the best estimate of the effect size. p Values <0.0045 
were regarded as signiﬁ  cant after correcting for multiple testing 
(11 tests) applying the Bonferroni correction. 
  Second, pathway analysis was carried out using Ingenuity 
Pathway Analysis 8.6 (Ingenuity Systems,   http://www. 
ingenuity.com  ) in order to explore whether SNPs uniquely asso-
ciated with either RA or SLE identiﬁ  ed characteristic pathways. 
Bioinformatic analysis, using the Ingenuity Pathways Analysis 
library, identiﬁ  ed the pathways that were most supported by 
the dataset. Molecules from the dataset that were associated 
with a canonical pathway in Ingenuity’s knowledge base were 
considered for the analysis. Fisher’s exact test was used to cal-
culate a p value determining the probability that the association 
between the genes in the dataset and the canonical pathway is 
explained by chance alone. 
  Third, analysis of carriage of SLE alleles in patients with RA 
was carried out using STATA version 9.2 to determine if there is 
an overall enrichment of SLE susceptibility variants in RA cases. 
A SLE loci carriage score was calculated by summing the num-
ber of SLE risk (coded as 1) and protection (coded as −1) alleles 
carried by each individual, and differences in the mean score 
between RA cases and controls was tested using the Wilcoxon 
rank-sum test. 
  Table  1         Association results for SLE risk variants genotyped in UK RA cases and controls   
 Chr   Locus   SNP 
 Major  allele/
minor allele   MAF  cases   MAF  controls   HWE  controls 
 Trend  test  
p   value 
 Corrected  
p   value    Allelic OR (95% CI) 
1  TNFSF4  rs10489265 T/G 0.25 0.24 0.56 0.11   1.05 (0.99 to 1.12)
4  BANK1  rs10516487 C/T 0.31 0.31 0.66 0.52   0.98 (0.93 to 1.04)
5  TNIP1  rs10036748 C/T 0.24 0.24 0.21 0.46   1.02 (0.96 to 1.09)
5  PTTG1  rs2431697 T/C 0.42 0.43 0.62 0.06   0.95 (0.90 to 1.00)
6  UHRF1BP1  rs11755393 A/G 0.34 0.34 0.41 0.79   1.01 (0.95 to 1.07)
6  ATG5  rs6568431 C/A 0.41 0.39 0.27 0.02 0.22 1.07 (1.01 to 1.13)
7  JAZF1  rs864745 G/A 0.49 0.49 0.98 0.20   1.03 (0.98 to 1.08)
8  BLK rs2736340 C/T 0.26 0.24 0.95 3.0×10  −4 3.3×10  −3  1.11 (1.05 to 1.17)
11   KIAA1542  rs4963128 G/A 0.32 0.34 0.96 0.02 0.22 0.93 (0.88 to 0.99)
16   ITGAM  rs9888739 C/T 0.10 0.11 0.42 0.16   0.94 (0.85 to 1.03)
22   UBE2L3  rs5754217 G/T 0.21 0.19 0.37 2.4×10  −3  0.026 1.11 (1.04 to 1.19)
      Linkage disequilibrium between the genotyped and reported variant (in brackets), when different:   TNFSF4   (rs2205960): r  2 =0.95;   TNIP1   (rs7708392): r  2 =0.90;   PTTG1   (rs2431099): 
r  2 =0.60;   JAZF1   (rs849142): r  2 =1;   ITGAM   (rs11860650): r  2 =0.92. 
  Chr, chromosome; CI, conﬁ  dence interval; HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; OR, odds ratio; RA, rheumatoid arthritis; SLE, systemic lupus 
erythematosus; SNP, single nucleotide polymorphism.     
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production of autoantibodies, antigen presentation to T cells 
and cytokine production, and B-cell depletion has proved suc-
cessful in the treatment of these diseases.    28      UBE2L3   encodes 
an ubiquitin-conjugating enzyme involved in the regulation of 
interferon and TLR7/9 signalling pathways.    4    Furthermore, this 
locus has been shown to be associated with coeliac disease.    29    
Therefore,   BLK   and   UBE2L3   are promising candidate genes for 
both RA and SLE. 
  The lack of association in our population between RA and 
markers mapping to   ITGAM   and   BANK1   is in accordance with a 
previous study in a Spanish population.    30    However, the Spanish 
study failed to detect association with   BLK  , probably owing to 
lack of power to detect modest effect sizes. In this regard, our 
study had >95% power to detect an association with similar 
effect sizes as those previously reported for SLE at the 5% sig-
niﬁ  cance level for all the loci tested. 
  All the shared SLE–RA loci and RA-only loci are involved in 
important pathways for autoimmunity and inﬂ  ammation. On 
the other hand, the burden of immune pathways seems to be 
lower for genes associated with SLE only. However, pathway 
analysis results should be considered with caution since, for 
most of the disease-associated loci, the true causal variant and 
therefore the gene responsible for the association has not yet 
been identiﬁ  ed. In addition, the exact role of several associated 
genes has not been elucidated and our knowledge of the rela-
tionships between molecules is limited. 
  The degree of genetic overlap between RA and SLE is sub-
stantial, but it is difﬁ  cult to assess and likely to be an under-
estimate, based on several factors. First, we have only analysed 
associated loci at genome-wide signiﬁ  cance levels; however, 
additional SLE loci not yet satisfying this criterion have been 
identiﬁ   ed and there are probably more to be discovered. 
Second, large sample sizes were included in the studies under-
taken in SLE leading to the identiﬁ  cation of variants with small 
effects, for which studies in RA may be underpowered to 
detect. Third, as only the SNP identiﬁ  ed in the primary study 
is tested in the other diseases, it may be that a different variant 
in the same gene/region is responsible for risk in the second 
disease. 
  There are already examples of loci common to two or more 
autoimmune diseases for which the associated SNP and/or allele 
is not the same in each disease. For example, the SNPs at the 
  TNFAIP3   region, associated with RA, SLE, type 1 diabetes, are 
different from those associated with coeliac disease and psoria-
sis.    20        31     –      36    Another example is the R620W variant of the   PTPN22   
gene, which has been widely associated with many autoimmune 
diseases but not psoriasis,    37        38    for which evidence of association 
of two different   PTPN22   SNPs (rs1217414 and rs3789604) has 
been found and this has been independently replicated.    39        40    In 
addition, with regard to the   JAZF1   locus, the variant associated 
with prostate cancer    41    differs from that associated with SLE,    10    
type 2 diabetes    42    and height variation.    43    For these reasons, the 
actual overlap between the two diseases may be higher than 
estimated in this study. 
  A high degree of overlap between SLE and RA susceptibil-
ity loci might be expected as the two diseases show some 
clinical overlap in joint involvement, autoantibody production, 
systemic features and response to treatments such as B-cell 
depletion (rituximab). Indeed, there was a proposal put forward 
for an overlap syndrome of ‘rhupus’ as some patients develop 
features of both diseases.    44    For example, the frequency of anti-
nuclear antibody, the hallmark of SLE, is higher in patients with 
RA than the general population.    45    Unfortunately, antinuclear 
and including data from GWAS. In this expanded analysis, the 
rs5754217 at the   UBE2L3   locus now reaches genome-wide sig-
niﬁ  cance (p=2.3×10  –10  , OR=1.14 95% CI 1.09 to 1.19). 
  We next performed a pathway analysis including the loci 
that have shown evidence of association with both SLE and 
RA (  HLA-DRB1  ,   PTPN22  ,   STAT4, TNFAIP3, FCGR2A, PRDM1, 
IRF5, PXK, BLK   and   UBE2L2  ). All the over-represented path-
ways are involved in the immune response, such as dendritic 
cell maturation, T helper (Th) cell differentiation or CTLA4 
signalling in cytotoxic T lymphocytes (  table 2  ). As is the case 
in the overlapping loci, genes exclusively associated with RA 
(  AFF3, ANKRD55/IL6ST, C5orf13, CCL21, CCR6, CD2/CD58, 
CD28, CD40, CTLA4, IL2/IL21, IL2RA, IL2RB, KIF5A, PRKCQ, 
PTPRC, RBPJ, REL, SPRED2, TAGAP, TRAF1/C5   and   TRAF6  ) 
are part of immune response pathways, with pathways related 
to Th cell activation being most over-represented. However, 
when analysing genes associated only with SLE (  ATG5, 
BANK1, ITGAM, JAZF1, PHRF1, PTTG1, TNFSF4, TNIP1   and 
  UHRF1BP1  ), a different pattern emerged. Four signiﬁ  cantly over-
represented pathways were identiﬁ  ed but each included only 
one gene and only one of them was immune response related 
(  table 2  ).   
  The number of SLE-associated SNPs showing at least nomi-
nal evidence for association with RA was higher than would be 
expected by chance alone. We explored, therefore, the extent 
of the total burden of SLE susceptibility alleles in RA. For this 
analysis we included previously generated genotype data for 
the markers: rs7574865 in   STAT4  , rs2476601 in   PTPN22   and 
rs5029937 in   TNFAIP3  ; and from this study: rs10489265 in 
  TNFSF4,   rs10516487 in  BANK1,   rs10036748 in  TNIP1  , rs2431697 
in   PTTG1  , rs11755393 in   UHRF1BP1,   rs6568431 in   ATG5,   
rs864745 in   JAZF1,   rs2736340 in   BLK,   rs4963128 in   KIAA1542,   
rs9888739 in   ITGAM   and rs5754217 in   UBEL2L3  . We found that 
the mean number of SLE risk alleles carried by patients with RA 
was signiﬁ  cantly higher than that found in controls (2.9 vs 2.5, 
p=9.1× 10  −7  ). 
  Finally, we calculated the sibling recurrence risk ratio (λs) for 
the conﬁ  rmed RA and SLE overlapping loci (  PTPN22  ,   STAT4, 
TNFAIP3, FCGR2A, PRDM1, IRF5, PXK, BLK   and   UBE2L2  ). We 
estimate that, after excluding   HLA-DRB1   alleles, these explain 
5.8% of the genetic susceptibility to RA as a whole, while all 
the non-HLA conﬁ  rmed RA loci identiﬁ  ed to date    24    are able to 
explain 10.7%.   
  DISCUSSION 
  The ﬁ  ndings conﬁ  rm the association of the   BLK   and   UBE2L3   
loci with RA thus adding to the list of loci showing overlap 
between RA and SLE, which currently include   HLA-DRB1  , 
  PTPN22  ,   STAT4, TNFAIP3, FCGR2A, PRDM1, IRF5   and   PXK  . In 
addition, two loci,   ATG5   and   KIAA1542  , showed nominal asso-
ciation with RA and the associated allele was the same as that 
previously reported for SLE, although the associations did not 
remain statistically signiﬁ  cant after Bonferroni correction was 
applied. However, the effect sizes conferred by   BLK  ,   ATG5   and 
  KIAA1542   were signiﬁ  cantly higher for SLE than for RA (test 
of heterogeneity of ORs p values=1×10  −6  , 3×10  −3   and 4×10  −3  , 
respectively). 
  The ﬁ  nding of an association with   BLK   conﬁ  rms a study in a 
US population where this locus was also associated with RA.    25    
Interestingly, the   BLK   locus has also shown association with RA 
in a Japanese population.    26      BLK   encodes a tyrosine kinase that 
is involved in the regulation of B-cell activation.    27    B cells have 
a key role in the pathogenesis of both RA and SLE through the 
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  Table  2         Over-represented (p<0.05) canonical pathways in which RA and SLE overlapping loci, RA only loci and SLE only loci are involved  
 Canonical  pathway    Type of pathway   p  Value    Genes in pathway 
SLE/RA overlap
Dendritic cell maturation Cellular immune response, cytokine signalling, pathogen-inﬂ  uenced 
signalling
1.4×10  −4   STAT4, FCGR2A, HLA-DRB1 
T helper cell differentiation Cellular immune response, cytokine signalling 9.8×10  −4   STAT4, HLA-DRB1 
CTLA4 signalling in cytotoxic T lymphocytes Cellular immune response 1.8×10  −3   HLA-DRB1, PTPN22 
Role of NFAT in regulation of the immune 
response
Cellular immune response, humoral immune response, intracellular 
and second messenger signalling
6.2×10  −3   FCGR2A, HLA-DRB1 
TNFR2 signalling Apoptosis, cytokine signalling 0.02   TNFAIP3 
B-cell development Cellular growth, proliferation and development, humoral immune 
response
0.02   HLA-DRB1 
Antigen presentation pathway Cellular immune response, humoral immune response 0.03   HLA-DRB1 
Allograft rejection signalling Cellular immune response, disease speciﬁ  c pathway 0.03   HLA-DRB1 
Autoimmune thyroid disease signalling Cellular immune response, disease speciﬁ  c pathway, humoral 
immune response
0.03   HLA-DRB1 
Graft-versus-host disease signalling Cellular immune response, disease speciﬁ  c pathway 0.03   HLA-DRB1 
TNFR1 signalling Apoptosis, cytokine signalling 0.03   TNFAIP3 
Nur77 signalling in T lymphocytes Apoptosis, cellular immune response, Nuclear receptor signalling 0.04   HLA-DRB1 
Calcium-induced T lymphocyte apoptosis Apoptosis, cellular immune response 0.04   HLA-DRB1 
CD40 signalling Cellular immune response, humoral immune response 0.04   TNFAIP3 
IL-10 signalling Cellular immune response, cytokine signalling 0.04   FCGR2A 
JAK/Stat signalling Apoptosis, cellular growth, proliferation and development, 
intracellular and second messenger signalling
0.04   STAT4 
RA only
iCOS-iCOSL signalling in T helper cells Cellular immune response 9.8×10  −9   PTPRC, CD28, PRKCQ, CD40, IL2RA, IL2RB 
T helper cell differentiation Cellular immune response, cytokine signalling 5.2×10  −8   IL21, IL6ST, CD28, CD40, IL2RA 
Altered T-cell and B-cell signalling in RA Cellular immune response, disease-speciﬁ  c pathways 6.6×10  −6   IL21, CD28, CD40, CCL21 
T-cell receptor signalling Cellular immune response 1.3×10  −5   PTPRC, CD28, PRKCQ, CTLA4 
IL-12 signalling and production in macrophages Cellular immune response, cytokine signalling 2.0×10  −5   TRAF6, PRKCQ, CD40, REL 
CD28 signalling in T helper cells Cellular immune response 2.7×10  −5   PTPRC, CD28, PRKCQ, CTLA4 
CD40 signalling Cellular immune response, humoral immune response 1.0×10  −4   TRAF6, CD40, TRAF1 
Cross-talk between dendritic cells and natural 
killer cells
Cellular immune response 3.7×10  −4   CD28, CD40, IL2RB 
B cell development Cellular growth, proliferation and development, humoral immune 
response
9.3×10  −4   PTPRC, CD40 
Systemic lupus erythematosus signalling Disease-speciﬁ  c pathways 1.0×10  −3   PTPRC, CD28, CD40 
Role of macrophages, ﬁ  broblasts and endothelial 
cells in rheumatoid arthritis
Disease-speciﬁ  c pathways 1.2×10  −3   TRAF6, IL6ST, PRKCQ, TRAF1 
NF- B signalling Cellular immune response, cytokine signalling, humoral immune 
response, organismal growth and development
1.3×10  −3   TRAF6, PRKCQ, CD40 
April -mediated signalling Apoptosis 1.5×10  −3   TRAF6, TRAF1 
Dendritic cell maturation Cellular immune response, cytokine signalling, pathogen-inﬂ  uenced 
signalling
1.6×10  −3   TRAF6, CD40, CD58 
B-cell activating factor signalling Cellular growth, proliferation and development, humoral immune 
response
1.7×10  −3   TRAF6, TRAF1 
Allograft rejection signalling Cellular immune response, disease-speciﬁ  c pathways 1.8×10  −3   CD28, CD40 
Autoimmune thyroid disease signalling Cellular immune response, disease-speciﬁ  c pathways, humoral 
immune response
1.9×10  −3   CD28, CD40 
Primary immunodeﬁ  ciency signalling Cellular immune response, disease-speciﬁ  c pathways, humoral 
immune response
2.3×10  −3   PTPRC, CD40 
IL-2 signalling Cellular immune response, cytokine signalling 3.1×10  −3   IL2RA, IL2RB 
Lymphotoxin   receptor signalling Apoptosis 3.2×10  −3   TRAF6, TRAF1 
Activation of IRF by cytosolic pattern recognition 
receptors
Cellular immune response 4.1×10  −3   TRAF6, CD40 
Small cell lung cancer signalling Cancer, disease-speciﬁ  c pathways 5.5×10  −3   TRAF6, TRAF1 
Communication between innate and adaptive 
immune cells
Cellular immune response 5.8×10  −3   CD28, CD40 
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antibody data were not available for the RA samples tested here 
so we were not able to explore whether the associations seen 
were greater in the antinuclear antibody-positive subgroup. 
  In conclusion, this study has shown that a high degree of 
overlap exists between RA and SLE and raises the possibility 
that shared phenotypic characteristics may be a result of shared 
genetic susceptibility loci implicated in overlapping inﬂ  amma-
tory pathways.     
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